Streetbeat News

Products Services

BYDDY

TM

BYD Co Ltd has launched its third electric vehicle model, the BYD Seal sedan, in Japan, directly competing with Toyota's RAV4 PHEV. The Seal will be available in two variants, with deliveries starting in July and August. BYD is offering an introductory discount for the first 1,000 customers.

Portfolio Pulse from Anan Ashraf

June 25, 2024 | 12:18 pm

ABBV

AbbVie received a Complete Response Letter (CRL) from the FDA for its New Drug Application (NDA) for ABBV-951, a treatment for motor fluctuations in advanced Parkinson's disease. The CRL was based on observations from an inspection at a third-party manufacturing facility and did not involve safety, efficacy, or labeling issues of ABBV-951. AbbVie is working with the FDA to address the concerns and bring the drug to market as soon as possible.

Portfolio Pulse from Benzinga Newsdesk

June 25, 2024 | 12:17 pm

XERI

Xeriant has provided an update on the production and certification of its eco-friendly NEXBOARD construction panels. The company has executed a second pilot production run with a U.S. contract manufacturer and is enhancing panel properties through internal and third-party testing. Modifications are being finalized to improve weight and rigidity.

Portfolio Pulse from Benzinga Newsdesk

June 25, 2024 | 12:16 pm

HUMA

Humacyte, Inc. (NASDAQ:HUMA) presented positive preclinical data for its BioVascular Pancreas (BVP) program, a potential treatment for type 1 diabetes. The BVP product candidate showed promising results in restoring normal blood glucose levels in diabetic mice and demonstrated islet survival and continued insulin production in non-human primate models.

Portfolio Pulse from Benzinga Newsdesk

June 25, 2024 | 12:14 pm

IMMP

Immutep Limited has signed an exclusive license agreement with Cardiff University to develop and commercialize next-generation anti-LAG-3 molecules for cancer treatment. This collaboration has identified promising compounds that block LAG-3, an immune checkpoint that reduces the immune system's response to fight cancer.

Portfolio Pulse from Benzinga Newsdesk

June 25, 2024 | 12:14 pm

LOBO

LOBO EV Technologies Ltd. (NASDAQ:LOBO) has strengthened its partnership with a well-established Brazilian electric mobility dealer following a successful on-site inspection. This visit has bolstered the Brazilian team's confidence in LOBO's production capabilities and professional services, enhancing their relationship.

Portfolio Pulse from Benzinga Newsdesk

June 25, 2024 | 12:13 pm

STLA

Stellantis NV (NYSE:STLA) has warned the UK government that it may cease vehicle production in the country if the government does not relax its electric vehicle (EV) sales targets. Stellantis has invested £100 million to convert its Ellesmere Port factory into an electric-only plant but finds the current EV sales targets 'unsustainable.'

Portfolio Pulse from Rounak Jain

June 25, 2024 | 12:12 pm

MNPR

Monopar Therapeutics Inc. (NASDAQ:MNPR) announced that its abstract on the evaluation of an anti-uPAR antibody as a radiopharmaceutical for imaging and treatment of solid tumors has been accepted as a 'Top-Rated Oral Presentation' at the EANM 2024 Annual Congress.

Portfolio Pulse from Benzinga Newsdesk

June 25, 2024 | 12:12 pm

BIVI

BioVie Inc. presented the protocol design for its upcoming SUNRISE-PD Phase 2 trial of bezisterim (NE3107) in early Parkinson's disease patients at the ATMRD 2024 Congress. The trial will evaluate the drug's effect on motor and non-motor symptoms in approximately 60 patients. Data from an earlier Phase 2a trial were also highlighted.

Portfolio Pulse from Benzinga Newsdesk

June 25, 2024 | 12:11 pm

CRL

Charles River Laboratories (NYSE:CRL) has announced a strategic collaboration with the Gates Institute at the University of Colorado Anschutz Medical Campus to develop GMP-grade lentiviral vectors for CAR T-cell therapies targeting hematological cancers.

Portfolio Pulse from Benzinga Newsdesk

June 25, 2024 | 12:11 pm